ASTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Astrana Health Inc (ASTH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown recent price growth and has optimistic analyst ratings, the company's financial performance is concerning, with significant declines in net income, EPS, and gross margin. Additionally, the absence of strong trading signals and neutral sentiment from hedge funds and insiders suggests a lack of immediate upward momentum. The upcoming earnings report on March 2, 2026, could provide more clarity, but for now, holding off on investment is recommended.
The MACD is positive and expanding, suggesting bullish momentum, but the RSI is neutral at 64.914, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 20.661), which could limit further short-term upside.
Analysts maintain a Buy rating with long-term growth potential driven by value-based care and organic growth opportunities.
Recent price increase of 4.81% in regular trading suggests short-term optimism.
Poor financial performance in Q3 2025, with net income and EPS dropping over 96% YoY.
Bearish moving averages and the stock trading near resistance levels limit immediate upside potential.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q3 2025, revenue increased by 99.71% YoY, but net income dropped by 97.68%, EPS fell by 96.97%, and gross margin declined by 38.32%. This indicates significant profitability challenges despite revenue growth.
Analysts are optimistic about long-term growth, with BTIG lowering the price target to $40 but maintaining a Buy rating, and Needham initiating coverage with a $28 price target. However, macro challenges and high medical trends could pressure the company unless management provides strong guidance.
